Ocrelizumab excites ECTRIMS | Nature Reviews Neurology

Access through your institution Buy or subscribe Ocrelizumab, a humanized monoclonal antibody that depletes CD20+ B cells, looks set to transform treatment of both relapsing–remitting and

progressive multiple sclerosis (MS), following success in three phase III trials that were presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

congress in October. The efficacy of ocrelizumab in relapsing–remitting MS was tested in the identical OPERA I and II trials, in which ocrelizumab was compared with IFN-β1a. Treatment was

administered in 24-week cycles to 1,656 patients with active disease and gadolinium-enhancing lesions. Over 2 years, the relapse rate was ∼47% lower in patients treated with ocrelizumab than

in patients treated with IFN-β1a. Ocrelizumab also reduced the risk of confirmed disability progression by 40% after 12 and 24 weeks of treatment. Furthermore, patients treated with

ocrelizumab had 95% fewer gadolinium-enhancing lesions than did patients treated with IFN-β1a. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access

through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink *

Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional

subscriptions * Read our FAQs * Contact customer support Authors * Ian Fyfe View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS

Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Fyfe, I. Ocrelizumab excites ECTRIMS. _Nat Rev Neurol_ 11, 667 (2015). https://doi.org/10.1038/nrneurol.2015.210 Download

citation * Published: 03 November 2015 * Issue Date: December 2015 * DOI: https://doi.org/10.1038/nrneurol.2015.210 SHARE THIS ARTICLE Anyone you share the following link with will be able

to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing

initiative